# Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

### A Randomized Controlled Trial

Andrea Z. LaCroix, PhD
Rowan T. Chlebowski, MD, PhD
JoAnn E. Manson, MD, DrPH
Aaron K. Aragaki, MS
Karen C. Johnson, MD, MPH
Lisa Martin, MD
Karen L. Margolis, MD, MPH
Marcia L. Stefanick, PhD
Robert Brzyski, MD, PhD
J. David Curb, MD, MPH
Barbara V. Howard, PhD
Cora E. Lewis, MD, MSPH
Jean Wactawski-Wende, PhD
for the WHI Investigators

HE WOMEN'S HEALTH INITIAtive (WHI) Estrogen-Alone Trial was a double-blind, placebo-controlled, randomized clinical trial evaluating the effects of conjugated equine estrogens (CEE) on chronic disease incidence among postmenopausal women with prior hysterectomy. The trial intervention was stopped 1 year early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned termination date. Analyses of outcomes during the intervention period suggested that treatment effects differed by age; compared with older women, younger women receiving CEE had a lower risk

For editorial comment see p 1354.

**Context** The Women's Health Initiative Estrogen-Alone Trial was stopped early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned trial termination date. Postintervention health outcomes have not been reported.

**Objective** To examine health outcomes associated with randomization to treatment with conjugated equine estrogens (CEE) among women with prior hysterectomy after a mean of 10.7 years of follow-up through August 2009.

**Design, Setting, and Participants** The intervention phase was a double-blind, placebo-controlled, randomized clinical trial of 0.625 mg/d of CEE compared with placebo in 10739 US postmenopausal women aged 50 to 79 years with prior hysterectomy. Follow-up continued after the planned trial completion date among 7645 surviving participants (78%) who provided written consent.

**Main Outcome Measures** The primary outcomes were coronary heart disease (CHD) and invasive breast cancer. A global index of risks and benefits included these primary outcomes plus stroke, pulmonary embolism, colorectal cancer, hip fracture, and death.

**Results** The postintervention risk (annualized rate) for CHD among women assigned to CEE was 0.64% compared with 0.67% in the placebo group (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.75-1.25), 0.26% vs 0.34%, respectively, for breast cancer (HR, 0.75; 95% CI, 0.51-1.09), and 1.47% vs 1.48%, respectively, for total mortality (HR, 1.00; 95% CI, 0.84-1.18). The risk of stroke was no longer elevated during the post-intervention follow-up period and was 0.36% among women receiving CEE compared with 0.41% in the placebo group (HR, 0.89; 95% CI, 0.64-1.24), the risk of deep vein thrombosis was lower at 0.17% vs 0.27%, respectively (HR, 0.63; 95% CI, 0.41-0.98), and the risk of hip fracture did not differ significantly and was 0.36% vs 0.28%, respectively (HR, 1.27; 95% CI, 0.88-1.82). Over the entire follow-up, lower breast cancer incidence in the CEE group persisted and was 0.27% compared with 0.35% in the placebo group (HR, 0.77; 95% CI, 0.62-0.95). Health outcomes were more favorable for younger compared with older women for CHD (P=.05 for interaction), total myocardial infarction (P=.007 for interaction), colorectal cancer (P=.04 for interaction), total mortality (P=.04 for interaction), and global index of chronic diseases (P=.009 for interaction).

**Conclusions** Among postmenopausal women with prior hysterectomy followed up for 10.7 years, CEE use for a median of 5.9 years was not associated with an increased or decreased risk of CHD, deep vein thrombosis, stroke, hip fracture, colorectal cancer, or total mortality. A decreased risk of breast cancer persisted.

Trial Registration clinicaltrials.gov Identifier: NCT00000611

JAMA. 2011;305(13):1305-1314

www.jama.com

of coronary heart disease (CHD), colorectal cancer, total death, and the global index of chronic diseases. However, the tests for interaction of age with

Author Affiliations are listed at the end of this article. Corresponding Author: Andrea Z. LaCroix, PhD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-A410, PO 19024, Seattle, WA 98109 (alacroix@whi.org).

©2011 American Medical Association. All rights reserved.

(Reprinted) JAMA, April 6, 2011—Vol 305, No. 13 **1305** 

treatment were only statistically significant for colorectal cancer.<sup>1</sup>

All previous reports of this trial were limited to outcomes occurring during the intervention phase. Herein, we report data on postintervention outcomes through a mean of 10.7 years of follow-up. This preplanned analysis had 3 objectives: (1) to assess the long-term effects of the CEE intervention on health outcomes; (2) to determine whether effects of CEE on health outcomes differed between the intervention and postintervention periods; and (3) to determine if previously identi-

fied suggestions of age-specific differences in effects of CEE on health outcomes persisted after stopping the intervention.

#### **METHODS**

#### **Intervention Phase**

Details of the WHI Estrogen-Alone Trial have been published.<sup>1,2</sup> Briefly, postmenopausal women aged 50 to 79 years were recruited at 40 US clinical centers between 1993 and 1998. Women were eligible if they had a prior hysterectomy, were not taking hormone therapy, and had an anticipated 3-year

survival. Women were excluded if they had prior breast cancer or other cancer within 10 years (except non-melanoma skin cancer), or prior venous thromboembolism (if screened after 1997). The study protocol was approved by institutional review boards at the participating institutions and all participants provided written informed consent.


A total of 10 739 women were randomly assigned to receive orally either 0.625 mg/d of CEE (Premarin, Wyeth Ayerst, Philadelphia, Pennsylvania) or matching placebo. Randomization was implemented at the WHI Clinical Coordinating Center using a permuted block algorithm, stratified by clinical center and age group. The clinical trial target size of 12 375 was calculated to provide 81% power to detect a 21% reduction in CHD at 9 years of followup. With the actual randomized sample size, the power estimate was 72% for a 21% reduction in CHD.

When the intervention phase ended after a mean of 7.1 years on February 29, 2004, vital status was known for 95% of participants, of whom 5.4% were deceased. By this time, 54% of participants had stopped taking their study medication. Median time receiving treatment was 5.9 years in the CEE group vs 5.8 years in the placebo group (interquartile range, 2.5-7.3 years). The median adherent time receiving treatment (ingestion of >80% of study pills) was 3.5 years in both groups (interquartile range, 1.5-6.5 years).

Clinical outcomes were collected through semiannual mailed question-naires and annual clinic visits. Outcomes were verified<sup>3</sup> initially by trained physician adjudicators at the local clinical centers by medical record review, followed by final adjudication at the WHI Clinical Coordinating Center. All adjudicators were blinded to treatment assignment.

Demographic characteristics and medical history were collected by selfreport using standardized questionnaires. Race/ethnicity was reported by participants within predefined categories matching the US Census. This in-

**Figure 1.** Women's Health Initiative Hormone Therapy Estrogen-Alone Trial Through Extended Follow-up



The intervention phase ran from December 1, 1993, to February 29, 2004. The postintervention phase began on March 1, 2004, the day participants were instructed to stop study medication use (conjugated equine estrogens or placebo) and continued through the original trial completion date (March 31, 2005). The postintervention extension phase began on April 1, 2005, and includes follow-up for participants who provided additional consent (78% of those eligible) through August 14, 2009.

**1306** JAMA, April 6, 2011—Vol 305, No. 13 (Reprinted)

©2011 American Medical Association. All rights reserved.

formation was required by the funding agency to monitor nonwhite representation in the trial.

## Postintervention Period and Extension

The postintervention period began on March 1, 2004, when participants were instructed to discontinue taking the study pills. The current report reflects a mean (SD) postintervention follow-up duration of 47.2 (20.7) months through August 14, 2009. After the protocol-specified termination date of March 31, 2005, subsequent participant follow-up required additional written consent, which was obtained from 77.9% of surviving participants in the CEE group (n=3778) and 78.4% of surviving participants in the placebo group (n=3867). The outcomes identified from the annual mailed questionnaires were verified by medical record review as described.3 Annual mammograms were encouraged and tracked by annual mammography report review. During the postintervention period, 3.6% to 4.7% of women from the CEE group and 2.7% to 3.0% of women from the placebo group reported estrogenalone use (any route of administration) on annual questionnaires.

#### **Statistical Analyses**

The primary analyses included all randomized participants using time-to-event methods and were based on the intention-to-treat principle as described previously. Thus, all participants were included in the analyses according to their randomized group assignment until they provided their last follow-up information (FIGURE 1). Baseline characteristics for women who provided additional consent were compared by randomization group using  $\chi^2$  and t test statistics.

Annualized rates of clinical events were estimated for the intervention period, the postintervention period, and the entire follow-up period by dividing the number of events by the corresponding person-time in each phase. Cumulative incidence curves were drawn for each trial phase with

quintiles of intended duration of intervention (ie, elapsed time from randomization until the intervention ended on February 29, 2004). The hazard ratios (HRs) were estimated using Cox proportional hazards models<sup>5</sup> stratified by age, prior disease (if appropriate), and randomization status in the WHI Dietary Modification Trial.<sup>6</sup> Models were constructed for each clinical end point in which women contributed follow-up time until the end of the interval, the date

of their first relevant clinical event, or the date of death or withdrawal from the study (whichever came first). Formal tests of the differences between the HRs in the intervention compared with the postintervention phase were calculated by inclusion of a binary term for trial phase as a timedependent variable as described.<sup>4</sup> Absolute rates and attributable risks (rate differences between CEE and placebo groups) also were calculated. All statistical tests were 2-sided.

	No. (%) of	Participants	
	CEE (n = 3778)	Placebo (n = 3867)	<i>P</i> Value <sup>b</sup>
Age group at screening, y	1000 (00 1)	1000 (01.0) —	
50-59	1223 (32.4)	1232 (31.9)	
60-69	1740 (46.1)	1799 (46.5)	.88
70-79	815 (21.6)	836 (21.6)	
Race/ethnicity White	2945 (78.0)	3001 (77.6) 7	
Black	514 (13.6)	565 (14.6)	
Hispanic	189 (5.0)	181 (4.7)	07
American Indian	31 (0.8)	18 (0.5)	.27
Asian/Pacific Islander	54 (1.4)	49 (1.3)	
Unknown	45 (1.2)	53 (1.4)	
Hormone therapy use			
Never	1929 (51.1)	1916 (49.6)	
Past	1304 (34.5)	1373 (35.5)	.43
Current	544 (14.4)	575 (14.9) 📙	
Duration of hormone therapy use, y <5	960 (51.9)	1036 (53.1) 7	
5-10	348 (18.8)	377 (19.3)	.52
>10	541 (29.3)	538 (27.6)	
BMIc			
<25	785 (20.9)	771 (20.1)	
25-<30	1289 (34.3)	1391 (36.2)	.21
≥30	1687 (44.9)	1683 (43.8)	
Smoking status Never	1988 (53.1)	1972 (51.5) 🏻	
Past	1417 (37.9)	1489 (38.9)	.30
Current	336 (9.0)	370 (9.7)	
Parity Never pregnant (no term pregnancy)	350 (9.3)	307 (8.0)	
≥1 term pregnancy	3400 (90.7)	3539 (92.0)	.04
Age at first birth, y	822 (27.0)	872 (27.3) 7	
20-29	2060 (67.7)	2128 (66.7)	.53
≥30	163 (5.4)	190 (6.0)	.00
Hysterectomy age group, y	, ,		
<40	1495 (39.8)	1501 (39.0)	
40-49	1643 (43.7)	1662 (43.2)	.17
50-54	345 (9.2)	412 (10.7)	
≥55	275 (7.3)	271 (7.0)	

(continued)

©2011 American Medical Association. All rights reserved.

(Reprinted) JAMA, April 6, 2011—Vol 305, No. 13 **1307** 

<b>Table.</b> Baseline Characteristics <sup>a</sup> (continued)					
	No. (%) of				
	CEE (n = 3778)	Placebo (n = 3867)	<i>P</i> Value <sup>b</sup>		
Medical history Bilateral oophorectomy	1370 (39.0)	1507 (41.8)	.01		
Treated diabetes (pills or injections)	243 (6.4)	250 (6.5)	.95		
Hypertensive (self-report or high blood pressure)	1806 (51.1)	1844 (51.2)	.92		
High cholesterol (requiring pills)	490 (14.3)	536 (15.5)	.16		
Statin use	288 (7.6)	302 (7.8)	.76		
Aspirin use ≥80 mg for ≥30 d	712 (18.8)	784 (20.3)	.12		
Angina	243 (6.5)	253 (6.6)	.82		
CABG or PTCA	69 (1.9)	70 (1.8)	.96		
Stroke	51 (1.3)	47 (1.2)	.60		
DVT or PE	65 (1.7)	60 (1.6)	.56		
Fracture and age ≥55 y	455 (16.5)	447 (15.8)	.51		
No. of times fell in last 12 mo	2368 (67.5)	2331 (65.2) 7			
1	680 (19.4)	722 (20.2)	.16		
2	296 (8.4)	346 (9.7)	.10		
≥3	164 (4.7)	174 (4.9)			

Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; CEE, conjugated equine estrogens; DVT, deep vein thrombosis; PE, pulmonary embolism; PTCA, percutaneous transluminal coronary angioplasty.

<sup>a</sup>This table contains data from Women's Health Initiative participants who consented to extended follow-up after en-

Nominal *P* values are reported without adjustment for multiple outcomes or sequential looks during the clinical trial follow-up period. Age-stratified subgroup analyses are reported for 10 outcomes. At the .05 level of significance, 0 to 1 interaction *P* values could be statistically significant based on chance alone.

To determine whether not providing consent to postintervention follow-up influenced risk estimates, inverse-probability weighting analyses were conducted using the methods described.4 Adherence sensitivity analyses also were conducted by censoring follow-up at 6 months after participants became nonadherent (ingestion of <80% of study pills or starting nonprotocol hormone therapy). For these analyses, participants who provided additional consent or were adherent were included in analyses that used the inverse of the participant's estimated reconsent or adherence probability as a weighting factor.

All statistical analyses were conducted using SAS software version 9.2

(SAS Institute Inc, Cary, North Carolina) and R software version 2.11 (R Foundation for Statistical Computing, http://www.r-project.org/).

#### **RESULTS**

#### **Baseline Characteristics**

Participant movement through the study is outlined in Figure 1. Among the women who provided additional consent, baseline characteristics remained similar to those previously published and were evenly distributed by randomized treatment assignment (TABLE). Small differences were observed for parity and bilateral oophorectomy between randomization groups. A comparison of the percentage of trial participants who consented to additional follow-up by treatment group is provided in eTable 1 at http://www.jama.com.

## Comparison of Intervention and Postintervention Findings

Incident clinical events by randomization assignment and corresponding HRs for the intervention, postinterven-

tion, and overall follow-up periods are summarized in FIGURE 2 and eTable 2 at http://www.jama.com. The HRs for CHD during the postintervention follow-up period were close to unity and similar to those observed during the intervention (Figure 2 and FIGURE 3). The increased stroke risk seen during the intervention phase was not present during the postintervention phase (0.36% [n=66] in the CEE group vs 0.41% [n=77] in the placebo group; HR, 0.89 [95% confidence interval {CI}, 0.64-1.24]; P = .05 for difference). Similarly, the increase in deep vein thrombosis and pulmonary embolism with CEE use compared with placebo during the intervention phase was not maintained during the postintervention phase (0.28% [n=52] vs 0.39% [n=74], respectively; HR, 0.72 [95% CI, 0.51-1.03]). For all cardiovascular events, the cumulative HR associated with CEE use was 1.06 (95% CI, 0.98-1.15) (2.26% in the CEE group [n=1146] vs 2.12% in the placebo group [n=1113]; Figure 2).

During the postintervention phase, 81.2% of women in the CEE group and 81.3% of women in the placebo group had at least 1 mammogram. The HRs comparing rates of invasive breast cancer in women randomized to CEE vs placebo were similar during the intervention (HR, 0.79; 95% CI, 0.61-1.02) and postintervention phases (HR, 0.75; 95% CI, 0.51-1.09) (Figure 2 and Figure 3). Consequently, a statistically significant lower cumulative breast cancer incidence of 0.27% was seen in the CEE group (n=151) compared with 0.35% in the placebo group (n=199) (HR, 0.77 [95% CI, 0.62-0.95]; P = .02). Colorectal cancer incidence did not differ between the women in the CEE group and the placebo group during the intervention or postintervention periods (Figure 2 and FIGURE 4).

The reduced hip fracture risk seen during the intervention phase with CEE was not maintained in the postintervention phase (0.36% in the CEE group [n=66] vs 0.28% in the placebo group [n=53]) (HR, 1.27 [95% CI, 0.88-1.82]; P=.01 for difference; Figure 2)

**1308** JAMA, April 6, 2011—Vol 305, No. 13 (Reprinted)

©2011 American Medical Association. All rights reserved.

rollment in the Estrogen-Alone Trial (April 2005).

bTest of association.

<sup>&</sup>lt;sup>C</sup>Calculated as weight in kilograms divided by height in meters squared.

resulting in an overall HR of 0.92 (95% CI, 0.71-1.18]; 0.20% in the CEE group [n=114] vs 0.22% in the placebo group

[n=127]). During the postintervention phase, hip fracture incidence was slightly higher in the CEE group com-

pared with the placebo group (Figure 4). Randomization to CEE did not influence total mortality or the

**Figure 2.** Effects of Conjugated Equine Estrogens (CEE) Compared With Placebo on Clinical Outcomes During the Intervention and Postintervention Phases in the Women's Health Initiative Estrogen-Alone Trial

	No. (%)	of Events			
Cardiovascular outcomes Overall CHD	CEE	Placebo	HR (95% CI)	P Value for Difference	Favors Favors CEE Placebo
Intervention Postintervention Overall	203 (0.55) 116 (0.64) 319 (0.58)	221 (0.58) 124 (0.67) 345 (0.61)	0.95 (0.78-1.15) 0.97 (0.75-1.25) 0.95 (0.82-1.11)	.90	
CHD death Intervention Postintervention Overall	63 (0.17) 42 (0.22) 105 (0.19)	66 (0.17) 51 (0.27) 117 (0.20)	0.98 (0.70-1.39) 0.84 (0.56-1.27) 0.92 (0.71-1.20)	].58	
Total MI Intervention Postintervention Overall	164 (0.44) 90 (0.50) 254 (0.46)	173 (0.45) 85 (0.46) 258 (0.45)	0.98 (0.79-1.21) 1.09 (0.81-1.47) 1.01 (0.85-1.20)	].55	
CABG or PTCA Intervention Postintervention Overall	256 (0.70) 130 (0.73) 386 (0.71)	277 (0.73) 115 (0.64) 392 (0.70)	0.93 (0.79-1.11) 1.14 (0.88-1.46) 0.99 (0.86-1.14)	.21	
Stroke Intervention Postintervention Overall	169 (0.45) 66 (0.36) 235 (0.42)	129 (0.34) 77 (0.41) 206 (0.36)	1.36 (1.08-1.71) 0.89 (0.64-1.24) 1.19 (0.98-1.43)	.05	
Deep vein thrombosis (DVT) Intervention Postintervention Overall	85 (0.23) 32 (0.17) 117 (0.21)	59 (0.15) 51 (0.27) 110 (0.19)	1.47 (1.06-2.05) 0.63 (0.41-0.98) 1.09 (0.84-1.41)	.003	-
Pulmonary embolism (PE) Intervention Postintervention Overall	52 (0.14) 35 (0.19) 87 (0.15)	39 (0.10) 37 (0.19) 76 (0.13)	1.37 (0.90-2.07) 0.98 (0.62-1.55) 1.18 (0.87-1.60)	.29	•
DVT or PE Intervention Postintervention Overall	111 (0.30) 52 (0.28) 163 (0.29)	86 (0.22) 74 (0.39) 160 (0.28)	1.32 (0.99-1.75) 0.72 (0.51-1.03) 1.05 (0.84-1.31)	.01	-
All cardiovascular events Intervention Postintervention Overall	874 (2.50) 272 (1.72) 1146 (2.26)	811 (2.23) 302 (1.86) 1113 (2.12)	1.11 (1.01-1.23) 0.93 (0.79-1.10) 1.06 (0.98-1.15)	.07	_ <b></b>
Cancer					
Invasive breast cancer Intervention Postintervention Overall	104 (0.28) 47 (0.26) 151 (0.27)	135 (0.35) 64 (0.34) 199 (0.35)	0.79 (0.61-1.02) 0.75 (0.51-1.09) 0.77 (0.62-0.95)	.76	
Colorectal cancer Intervention Postintervention Overall	65 (0.17) 24 (0.13) 89 (0.16)	58 (0.15) 24 (0.13) 82 (0.14)	1.15 (0.81-1.64) 1.01 (0.58-1.79) 1.11 (0.82-1.50)	].71	
All cancer types Intervention Postintervention Overall	404 (1.10) 203 (1.16) 607 (1.12)	439 (1.17) 220 (1.24) 659 (1.19)	0.94 (0.82-1.08) 0.93 (0.77-1.13) 0.94 (0.84-1.05)	.93	
Other outcomes Hip fracture Intervention Postintervention Overall	48 (0.13) 66 (0.36) 114 (0.20)	74 (0.19) 53 (0.28) 127 (0.22)	0.67 (0.46-0.96) 1.27 (0.88-1.82)	.01	<b>←</b>
Death (all causes) Intervention Postintervention Overall	300 (0.80) 277 (1.47) 577 (1.02)	297 (0.22) 297 (0.77) 284 (1.48) 581 (1.00)	0.92 (0.71-1.18) 1.04 (0.89-1.22) 1.00 (0.84-1.18) 1.02 (0.91-1.15)	.81	
Global index Intervention Postintervention Overall	752 (2.08) 442 (2.64) 1194 (2.26)	753 (2.04) 446 (2.62) 1199 (2.22)	1.03 (0.93-1.14) 1.02 (0.89-1.16) 1.03 (0.95-1.11)	.97	<b>→</b>
					0.50 0.67 1.00 1.50 2.00 HR (95% CI)

The hazard ratios (HRs) are derived from proportional hazards models stratified by prior disease (for outcomes in which women were eligible for enrollment with and without the prevalent condition), age, and dietary modification randomization group. The *P* values for differences between the intervention and postintervention phases were calculated from models for the overall mean follow-up period that also included a time-dependent term for trial phase. For the intervention and overall phases, time to event equals 0 on date of randomization. For the postintervention phase, time to event equals 0 on February 29, 2004. CABG indicates coronary artery bypass graft; CHD, coronary heart disease; CI, confidence interval; MI, myocardial infarction; and PTCA, percutaneous transluminal coronary angioplasty.

global index of chronic diseases either during the intervention phase or during the postintervention phase (Figure 2 and Figure 4).

#### **Age-Specific Comparisons**

The age-specific intervention results for a mean follow-up of 10.7 years are displayed in FIGURE 5. The overall HRs for CHD differed among women aged 50 to 59 years (HR, 0.59 [95% CI, 0.38-0.90]; 0.18% [n=33] in the CEE group vs 0.31% in the placebo group [n=56]) compared with older women in which the HRs were near unity (P=.05 for interaction). For total myocardial infarction (MI), the HR was 0.54 (95% CI, 0.34-0.86; 0.15% in the CEE group [n=27] vs 0.27% in the placebo group [n=50]) for women aged 50 to 59 years; 1.05 (95% CI, 0.82-1.35; 0.51%


[n=126] vs 0.48% [n=124], respectively) for women aged 60 to 69 years; and 1.23 (95% CI, 0.92-1.65; 0.82% [n=101] vs 0.66% [n=84], respectively) for women aged 70 to 79 years (P = .007 for interaction). A similar pattern was seen when time since menopause (as previously defined<sup>7</sup>) instead of age was examined for both coronary end points (data not shown). Overall, stroke risks were nonsignificantly elevated for all age groups (P=.91 for interaction). For deep vein thrombosis and pulmonary embolism, no agespecific differences emerged but the increased risks observed during the intervention phase subsided during the postintervention phase.

There were fewer invasive breast cancers in the CEE group compared with the placebo group in all 3 age groups

(P=.96 for interaction). The previously observed age interaction for colorectal cancer was significant throughout the entire follow-up period. Women aged 70 to 79 years at entry experienced a nearly 2-fold increased risk of colorectal cancer in the CEE group (0.30% [n=38] vs 0.16% in the placebo group [n=21]) (HR, 1.83 [95% CI, 1.08-3.12]; P=.04 for interaction).

The HRs for total mortality and the global index of chronic diseases differed by age as previously suggested.<sup>7</sup> Younger postmenopausal women (aged 50-59 years) who were randomized to CEE vs placebo had a lower risk of death (0.35% [n=65] vs 0.48% [n=89], respectively; HR, 0.73 [95% CI, 0.53-1.00]) compared with no increased risk among women in their 60s (1.00% [n=254] vs 0.96% [n=253], respec-

Figure 3. Cumulative Incidence of Coronary Heart Disease, Stroke, Pulmonary Embolism, and Invasive Breast Cancer



Vertical dotted lines represent quintiles of duration of intended intervention and follow-up in the study population (elapsed time from randomization until the end of the intervention on February 29, 2004). CEE indicates conjugated equine estrogens.

a Includes events from randomization to August 14, 2009.

<sup>b</sup>Includes events from March 1, 2004, to August 14, 2009

**1310** JAMA, April 6, 2011—Vol 305, No. 13 (Reprinted)

©2011 American Medical Association. All rights reserved.

tively; HR, 1.04 [95% CI, 0.88-1.24]), and a slight increased risk of death among women in their 70s (2.02% [n=258] vs 1.83% [n=239], respectively; HR, 1.12 [95% CI, 0.94-1.33]; P=.04 for interaction). A similar pattern was observed by age for women randomized to CEE vs placebo for the global index of chronic diseases with a possible overall benefit among younger women (aged 50-59 years: 1.04% [n=184] vs 1.22% [n=217], respectively; HR, 0.85 [95% CI, 0.70-1.03]) and possible harm among the oldest women (aged 70-79 years: 4.04% [n=466] vs 3.56% [n=423], respectively; HR, 1.15 [95% CI, 1.01-1.32]; P = .009 for interaction).


Expressed as absolute rates per 10 000 women annualized over the average follow-up period of 10.7 years, women aged 50 to 59 years who received CEE compared with women who received placebo had 12 fewer acute MIs, 13 fewer deaths, and 18 fewer adverse events in the global index of chronic diseases. In contrast, women aged 70 to 79 years who received CEE compared with women who received placebo had 16 excess MIs, 19 excess deaths, and 48 excess adverse events in the global index of chronic diseases.

#### **Sensitivity Analyses**

The results were similar when using inverse-probability weighting to account for censoring due to those not providing consent for postintervention follow-up. The HR for breast cancer for the cumulative follow-up period became 0.81 (95% CI, 0.64-1.01). Age-stratified results were virtually identical to those described herein with P values for interaction reflecting some loss of precision with the inverse-probability weights: CHD (P=.23); total MI (P=.01); colorectal cancer (P=.09); death (P=.13); and global index of chronic diseases (P=.02). In each case, women in their 50s had more favorable HRs than older women (aged 70-79 years).

The results also were similar when women were censored 6 months after becoming nonadherent to study medication during the intervention period. Adherence-adjusted HRs for the overall follow-up period using inverseprobability weighting showed an increased risk of stroke with CEE use (HR, 1.50; 95% CI, 1.11-2.05) and a lower risk of breast cancer (HR, 0.68; 95% CI, 0.49-0.95). No significant age

Figure 4. Cumulative Incidence of Colorectal Cancer, Hip Fracture, Death, and Global Index of Chronic Diseases



Vertical dotted lines represent quintiles of duration of intended intervention and follow-up in the study population (elapsed time from randomization until the end of the intervention on February 29, 2004). CEE indicates conjugated equine estrogens. <sup>a</sup>Includes events from randomization to August 14, 2009.

<sup>b</sup>Includes events from March 1, 2004, to August 14, 2009

interactions emerged for any outcome in the adherence-adjusted analyses; however, power was limited due to substantial censoring.


#### **COMMENT**

Among postmenopausal women with prior hysterectomy who stopped taking CEE after a median of 5.9 years of use, several patterns of health risks and benefits seen during the intervention period were not maintained during the postintervention period, while other trends persisted. For CHD (a primary trial end point), the HRs remained null after stopping the intervention and overall. The increases in risk of stroke

and venous thromboembolism seen among women randomized to CEE during the intervention period rapidly dissipated during the postintervention period as did the protective effect on risk of hip fracture. The lower incidence of breast cancer seen among women randomized to CEE during the intervention period became statistically significant with extended follow-up. Considering the entire follow-up period, rates of total mortality and the global index of chronic diseases were essentially the same in the CEE and placebo groups. Statistically significant age interactions for CEE use, suggesting greater safety and possible benefit among women in their 50s and potential harm among older women, were observed for CHD, total MI, colorectal cancer, total mortality, and the global index of chronic diseases.

The statistically significant reduction in breast cancer incidence seen with CEE use continued a trend that emerged during the intervention period. 8,9 This finding differs from the preponderance 10-12 but not all 13,14 observational studies that suggest CEE use, especially in lean women 15,16 and after long duration of exposure, 17 increases breast cancer incidence. We previously reported no significant differences by body mass index for CEE effects on breast cancer incidence among participants in this trial. 8

Figure 5. Cumulative Annualized Incidence Rates for Clinical Outcomes in the Women's Health Initiative Estrogen-Alone Trial According to 10-Year Age Groups at Enrollment



Annualized incidence rates were estimated for the overall follow-up period by dividing the number of events by the corresponding person-time for participants in each age stratum. The black squares indicate the HRs for the overall follow-up period. For comparison, the HRs for the intervention phase are shown as blue bars. CEE indicates conjugated equine estrogen; CHD, coronary heart disease; CI, confidence interval; MI, myocardial infarction.

Investigators from the Million Women Study have suggested, 18 based on recent findings, 9,19,20 that time from menopause (longer in the WHI vs shorter in usual clinical practice and observational study cohorts) may account for some of the differences in risk estimates from various studies. Alternatively, confounding by differential mammogram use in the observational studies (higher in estrogen users) may explain the finding of higher breast cancer incidence among hormone therapy users.20 Future subgroup analyses in this trial, which are beyond the scope of the current study, will explore this issue.

It is unlikely that diagnostic delay explains our breast cancer results because CEE only modestly influenced breast density21 and mammogram diagnostic performance.22 In terms of biological plausibility, preclinical<sup>23,24</sup> and clinical<sup>25</sup> studies suggest that the adaptive changes to gene expression profiles that occur during estrogen exposure and after estrogen deprivation<sup>26</sup> may render mammary tumors susceptible to inhibition by estrogen. In contrast to these results from the Estrogen-Alone Trial, the WHI combined Estrogen Plus Progestin Trial showed that treatment impeded mammographic accuracy, and was associated with significant increase in rates of both breast cancer incidence and breast cancer mortality.27-29

With extended follow-up, hip fracture cumulative incidence was the same in the CEE and placebo groups. Rates of hip fracture were somewhat higher among women in the CEE group compared with those in the placebo group after stopping the intervention. These results are consistent with studies showing accelerated bone loss<sup>30</sup> and a short-term increased risk of hip fracture among women who discontinue hormone therapy,<sup>31</sup> and no fracture risk reduction or elevation in past hormone therapy users.<sup>32,33</sup>

Our results suggest that women randomized to CEE while in their 50s had fewer CHD events than those randomized to placebo, findings that are sup-

ported by preclinical<sup>34</sup> and clinical data<sup>35-37</sup> but are not applicable to older women. In a subset of WHI participants aged 50 to 59 years at study entry, coronary artery calcium measurements, which are markers for atherosclerotic plaque burden, were lower following trial completion among women randomized to CEE vs placebo.35 Other support derives from nonhuman primate models36 and observational studies.<sup>38-40</sup> An important caveat is that study participants took unopposed estrogen for a median duration of less than 6 years and our results cannot be extrapolated to longer or shorter treatment durations.

Our results emphasize the need to counsel women about hormone therapy differently depending on their age and hysterectomy status. A postmenopausal woman who has had a hysterectomy and is considering initiation of CEE should be counseled about the increased risks of venous thromboembolism and stroke during treatment, which diminish with treatment cessation. Among younger women, no new safety concerns emerged and some risk reductions became apparent during the postintervention period. Among older women, risks of colorectal cancer, death, and the global index of chronic diseases were elevated over the cumulative follow-up period. The risks and benefits of CEE use for periods of longer than 5 to 6 years cannot be inferred from these data for any age group. Mechanisms underlying the reduced risks of breast cancer in all women, and coronary events in younger but not older women, warrant further study.

Author Affiliations: Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington (Dr LaCroix and Mr Aragaki); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California (Dr Chlebowski); Division of Preventive Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts (Dr Manson); Health Science Center, Department of Preventive Medicine, University of Tennessee, Memphis (Dr Johnson); Department of Cardiology, George Washington University, Washington, DC (Dr Martin); Berman Center for Clinical Research, University of Minnesota, Minneapolis (Dr Margolis); Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California (Dr Stefanick); Health

Science Center, University of Texas, San Antonio (Dr Brzyski); John A. Burns School of Medicine, University of Hawaii and Pacific Health Research Institute, Honolulu (Dr Curb); MedStar Research Institute, Hyattsville, Maryland (Dr Howard); Division of Preventive Medicine, University of Alabama, Birmingham (Dr Lewis); and Department of Social and Preventive Medicine, State University of New York, Buffalo (Dr Wactawski-Wende).

**Author Contributions:** Dr LaCroix had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Manson, Margolis, Stefanick, Wactawski-Wende.

Acquisition of data: LaCroix, Chlebowski, Manson, Johnson, Margolis, Stefanick, Brzyski, Curb, Howard, Wactawski-Wende.

Analysis and interpretation of data: LaCroix, Chlebowski, Manson, Aragaki, Johnson, Martin, Margolis, Curb, Howard, Lewis, Wactawski-Wende. Drafting of the manuscript: LaCroix, Manson, Aragaki. Critical revision of the manuscript for important intellectual content: LaCroix, Chlebowski, Manson, Johnson, Martin, Margolis, Stefanick, Brzyski, Curb, Howard, Lewis, Wactawski-Wende.

Statistical analysis: LaCroix, Aragaki.

Obtained funding: LaCroix, Chlebowski, Manson, Johnson, Stefanick, Curb, Howard, Lewis, Wactawski-Wende.

Administrative, technical, or material support: Chlebowski, Manson, Johnson, Brzyski, Curb, Lewis, Wactawski-Wende.

Study supervision: LaCroix, Johnson, Margolis, Curb, Howard, Wactawski-Wende.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr LaCroix reported serving on scientific advisory committees for research studies funded by Warner Chilcott and sanofi-aventis, Amgen, and Pfizer. Dr Chlebowski reported being a consultant for AstraZeneca, Novartis, Amgen, and Pfizer; receiving funding support from Amgen; and serving on speaker's bureaus for AstraZeneca and Novartis. Dr Howard reported receiving payment for lectures, serving on a speaker's bureau, and being a consultant for Merck/Schering-Plough Wyeth Research; and receiving research support through the donation of drugs from Merck/Schering-Plough. None of the other authors reported any financial disclosures.

Funding/Support: Wyeth Ayerst donated the study drugs. The Women's Health Initiative program is funded by the National Heart, Lung, and Blood Institute, the National Institutes of Health, and the US Department of Health and Human Services through contacts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.

Role of the Sponsor: Committees of the Women's Health Initiative investigators that included representatives from the National Heart, Lung, and Blood Institute (the study's sponsor) had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript. The Women's Health Initiative Project Office at the National Heart, Lung, and Blood Institute approved the manuscript but had no other role.

Women's Health Initiative Investigators: A full listing of Women's Health Initiative investigators can be found at http://whiscience.org/publications/WHI\_investigators\_longlist\_2005-2010.pdf.

Online-Only Material: eTable 1 and eTable 2 are available at http://www.jama.com.

**Additional Contributions:** We thank the Women's Health Initiative investigators and staff for their outstanding dedication and commitment.

©2011 American Medical Association. All rights reserved.

(Reprinted) JAMA, April 6, 2011—Vol 305, No. 13 1313

#### REFERENCES

- 1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004; 291(14):1701-1712.
- **2.** The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials*. 1998; 19(1):61-109.
- **3.** Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. *Ann Epidemiol*. 2003; 13(9)(suppl):S122-S128.
- **4.** Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA*. 2008; 299(9):1036-1045.
- **5.** Cox DR. Regression analysis and life tables. *J R Stat Soc [Ser A]*. 1972;34:187-220.
- **6.** Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*. 2006; 295(6):629-642.
- 7. Rossouw JE, Prentice RL, Manson JE, et al. Post-menopausal hormone therapy and risk of cardiovas-cular disease by age and years since menopause. *JAMA*. 2007;297(13):1465-1477.
- **8.** Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA*. 2006; 295(14):1647-1657.
- **9.** Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. *Am J Epidemiol*. 2008;167(12): 1407-1415.
- **10.** Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet*. 1997;350(9084):1047-1059.
- **11.** Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *N Engl J Med.* 1995; 332(24):1589-1593.
- **12.** Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003;362(9382):419-
- **13.** Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hor-

- mone therapy and risk of breast cancer. *JAMA*. 2003; 289(24):3254-3263.
- **14.** Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. *J Clin Oncol*. 2003;21(23):4314-4321.
- 15. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA*. 2000;283(4):485-491
- **16.** Calle EE, Feigelson HS, Hildebrand JS, et al. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. *Cancer.* 2009;115(5):936-945.
- 17. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med*. 2006;166(9):1027-1032.
- **18.** Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. *J Natl Cancer Inst.* 2011; 103(4):296-305.
- **19.** Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestin menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? *J Clin Oncol*. 2009;27(31):5138-5143.
- **20.** Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. *J Natl Cancer Inst.* 2011;103(4):284-285.
- 21. McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial. J Clin Oncol. 2009;27(36):6135-6143.
- **22.** Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. *J Clin Oncol*. 2010;28(16):2690-2697.
- **23.** Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen. *J Steroid Biochem Mol Biol*. 2005:95(1-5):155-165.
- **24.** Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. *Endocrinology*. 1998;139(10):4164-4174.
- **25.** Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer. *JAMA*. 2009;302(7):774-780
- **26.** Dunbier AK, Anderson H, Ghazoui Z, et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-

- positive breast cancer in postmenopausal women. *J Clin Oncol*. 2010;28(7):1161-1167.
- **27.** Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. *JAMA*. 2003;289(24):3243-3253.
- **28.** Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. *N Engl J Med*. 2009;360 (6):573-587
- **29.** Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. *JAMA*. 2010; 304(15):1684-1692.
- **30.** Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy. *Arch Intern Med.* 2002; 162(6):665-672.
- **31.** Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol*. 2004;103(3):440-446
- **32.** Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. *Ann Intern Med.* 1995;122(1):9-16.
- **33.** Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. *JAMA*. 2004; 291(18):2212-2220.
- **34.** Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. *Science*. 2005;308(5728):1583-1587.
- **35.** Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. *N Engl J Med*. 2007;356(25):2591-2602.
- **36.** Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. *Cardiovasc Res.* 2002;53(3):605-619.
- **37.** Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. *N Engl J Med*. 2003;348(7):645-650.
- **38.** Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? *Am J Epidemiol*. 2007;166(5):511-517.
- **39.** Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. *J Womens Health (Larchmt)*. 2006;15(1):35-44.
- **40.** Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology*. 2008; 19(6):766-779.